NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Copanlisib Hydrochloride
Biological: Durvalumab
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Procedure: X-Ray Imaging

First Posted Date: 2019-02-15

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT03842228

Locations: 🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 14 locations

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Phase 2

Recruiting

Conditions: Thyroid Cancer

Interventions: Drug: Thyrogen
Radiation: I-131
Radiation: I-124
Other: Thyroid hormone withdrawal

First Posted Date: 2019-02-15

Last Posted Date: 2025-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT03841617

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Elastography
Drug: Osimertinib
Procedure: Positron Emission Tomography
Drug: Telaglenastat Hydrochloride
Procedure: X-Ray Imaging

First Posted Date: 2019-02-06

Last Posted Date: 2025-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT03831932

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 8 locations

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Recruiting

Conditions: Mesothelioma
Families

First Posted Date: 2019-02-05

Last Posted Date: 2025-05-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1000

Registration Number: NCT03830229

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer

Active, not recruiting

Conditions: Primary Hemophagocytic Lymphohistiocytosis
Macrophage Activation Syndrome

First Posted Date: 2019-02-01

Last Posted Date: 2025-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT03827343

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Phase 1

Recruiting

Conditions: Myelodysplastic Syndrome With Excess Blasts
Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Drug: UAE Inhibitor TAK-243

First Posted Date: 2019-01-25

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT03816319

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions: Biological: Anetumab Ravtansine
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Biological: Nivolumab
Biological: Ipilimumab
Drug: Gemcitabine Hydrochloride

First Posted Date: 2019-01-25

Last Posted Date: 2025-05-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT03816358

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

and more 42 locations

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Psoriatic Arthritis
Rheumatoid Arthritis
Psoriasis
Ulcerative Colitis
Autoimmune Disease
Inflammatory Bowel Disease
Malignant Solid Neoplasm
Multiple Sclerosis
Systemic Scleroderma

Interventions: Procedure: Biospecimen Collection
Biological: Nivolumab

First Posted Date: 2019-01-25

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT03816345

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 49 locations

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Phase 1

Active, not recruiting

Conditions: Pathologic Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Basal Cell Carcinoma
Metastatic Merkel Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Unresectable Merkel Cell Carcinoma
Metastatic Melanoma

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Prednisone
Drug: Tacrolimus

First Posted Date: 2019-01-25

Last Posted Date: 2025-03-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03816332

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 4 locations

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome

Interventions: Drug: Azacitidine
Drug: Cytarabine
Drug: Fludarabine Phosphate
Drug: Methotrexate
Drug: Pevonedistat
Drug: Therapeutic Hydrocortisone

First Posted Date: 2019-01-23

Last Posted Date: 2025-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03813147

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy